OakChart

Biocryst Pharmaceuticals Inc

BCRXHealthcare·Drug Manufacturers - Specialty & Generic·USA·Small·NASD·Nov 11 • 3:59 PM ET

7.65+0.12 (1.59%)
2026-11-12 02:33 CET
Market cap
1,968.34 USD m
Revenue, TTM
961.51 USD m
Net income, TTM
-359.66 USD m
Free cash flow, TTM
348.92 USD m
EPS diluted, TTM
-1.42
P/E
-
Compare

Price

BCRX against its 20, 50 and 200-day averages
2050200beat
8.009.0010.0011.009.5M19.1MVolumeMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26BCRXclose 7.6520-day 7.9850-day 8.33200-day 8.797.6552w high

31.8% under the 52-week high of 11.22 on 9 Jul 2026. 52-week low 6.23 on 5 Feb 2026. Last 15 sessions, 20.1% high to low

Volume 0.54× normal · the line is the 50-bar volume average

Profile

BCRX
52-week range, 28% of the way up
6.2311.22

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

IndexRUT
Employees435
IPOMar 04, 1994
Beta0.53
ATR, 14d0.36
Rel volume0.54
Short float12.50%
Insider own14.04%
Inst own89.68%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap1.97B
Enterprise Value2.42B
Income-359.66M
Sales961.51M
Book/sh-1.55
Cash/sh1.46
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout0.00%
Employees435
IPOMar 04, 1994

Ratios

P/E-
Forward P/E13.59
PEG-
P/S2.05
P/B-
P/C5.24
P/FCF5.64
EV/EBITDA5.90
EV/Sales2.52
Quick Ratio2.64
Current Ratio2.71
Debt/Eq-
LT Debt/Eq-
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.42
EPS next Y0.56
EPS next Q0.09
EPS this Y-289.23%
EPS next Y124.58%
EPS next 5Y-19.02%
EPS past 3/5Y- -
Sales past 3/5Y47.82% 117.89%
EPS Y/Y TTM-3028.57%
Sales Y/Y TTM60.30%
EPS Q/Q141.40%
Sales Q/Q13.11%
EarningsNov 04 BMO
EPS/Sales Surpr.52.34% 8.83%

Ownership

Insider Own14.04%
Insider Trans-0.20%
Inst Own89.68%
Inst Trans3.88%
ROA-69.33%
ROE-
ROIC-93.75%
Gross Margin97.66%
Oper. Margin42.47%
Profit Margin-37.41%
SMA20-4.09%
SMA50-8.18%
SMA200-12.98%
Trades-

Technical

Shs Outstand256.12M
Shs Float221.18M
Short Float12.50%
Short Ratio5.61
Short Interest27.64M
52W High11.22 -31.82%
52W Low6.23 22.79%
Volatility5.35% 4.37%
ATR (14)0.36
RSI (14)41.27
Beta0.53
Rel Volume0.54
Avg Volume4.93M
Volume2,641,912

Performance

Perf Week-7.16%
Perf Month-5.20%
Perf Quarter-22.02%
Perf Half Y-20.31%
Perf YTD-1.92%
Perf Year5.81%
Perf 3Y53.61%
Perf 5Y-38.11%
Perf 10Y43.26%
Recom1.36
Target Price20.45
Prev Close7.53
Price7.65
Change %1.59%

Analyst ratings

latest 10 of 20
DateActionAnalystRating changeTargetImplied
Sep 10, 2026DowngradeRRBC Capital MktsOutperform → Sector Perform$11+43.8%
Jul 13, 2026ResumedJJP MorganNeutral$12+56.9%
Feb 18, 2026ResumedEEvercore ISIOutperform$17+122.2%
Oct 15, 2025ResumedTTD CowenBuy$30+292.2%
Oct 01, 2025DowngradeEEvercore ISIOutperform → In-line$8+4.6%
Apr 29, 2025InitiatedCCantor FitzgeraldOverweight$20+161.4%
Feb 25, 2025InitiatedWWedbushOutperform$15+96.1%
Nov 20, 2023ResumedJJP MorganOverweight$10+30.7%
Sep 18, 2023UpgradeRRBC Capital MktsSector Perform → Outperform$9 → $10+30.7%
Aug 04, 2023UpgradeJJefferiesHold → Buy$11+43.8%

Peers

Mkt cap
TickerCompanyMkt cap
PHVSPharvaris NV2.40B
TAKTakeda Pharmaceutical Co ADR66.58B
IONSIonis Pharmaceuticals Inc4.72B
NTLAIntellia Therapeutics Inc1.60B
HRMYHarmony Biosciences Holdings Inc2.01B
MIRMMirum Pharmaceuticals Inc6.18B
PTCTPTC Therapeutics Inc5.42B
RYTMRhythm Pharmaceuticals Inc7.78B
AGIOAgios Pharmaceuticals Inc1.96B
BMRNBiomarin Pharmaceutical Inc11.30B

Insider trading

latest 14 of 29
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
McKee Amy EDirectorMay 18 '26Sale8.9711,180100,28531,252May 19 04:07 PM
Amy McKeeDirectorMay 18 '26Proposed Sale8.9411,18099,906May 18 04:48 PM
Barnes Alane PChief Legal OfficerMay 13 '26Option Exercise5.0462,500315,000463,203May 15 04:08 PM
Barnes Alane PChief Legal OfficerMay 13 '26Sale9.5462,500596,250400,703May 15 04:08 PM
Barnes Alane POfficerMay 13 '26Proposed Sale9.5462,500596,250May 13 01:06 PM
HEGGIE THERESADirectorMar 20 '26Option Exercise6.3049,933314,578115,285Mar 24 04:02 PM
HEGGIE THERESADirectorMar 20 '26Sale10.1149,933504,82365,352Mar 24 04:02 PM
HEGGIE THERESADirectorMar 20 '26Proposed Sale10.1149,933504,620Mar 20 11:36 AM
Barnes Alane PChief Legal OfficerMar 16 '26Option Exercise5.51150,000826,500550,703Mar 18 04:11 PM
Barnes Alane PChief Legal OfficerMar 16 '26Sale9.15150,0001,372,500400,703Mar 18 04:11 PM
Barnes Alane POfficerMar 16 '26Proposed Sale9.15150,0001,372,007Mar 16 04:17 PM
Stonehouse Jon PDirectorMar 02 '26Option Exercise3.22305,995985,3041,629,845Mar 03 04:34 PM
Stonehouse Jon PDirectorMar 02 '26Proposed Sale8.65305,9952,646,857Mar 02 03:16 PM
Barnes Alane PChief Legal OfficerDec 22 '25Sale7.6521,773166,563398,751Dec 23 04:11 PM

Held by

AUM
TickerCompanyAUM
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
XBIState Street SPDR S&P Biotech ETFAUM: 10.50B
IWMiShares Russell 2000 Index FundAUM: 77.38B
VBVanguard Morningstar Small-Cap ETFAUM: 79.59B
VXFVanguard Extended Market Index ETFAUM: 30.47B
IWOiShares Russell 2000 Growth ETFAUM: 14.06B
VBKVanguard Morningstar Small-Cap Growth ETFAUM: 22.34B
IBBiShares Biotechnology ETFAUM: 11.36B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
SCHASchwab U.S. Small-Cap ETFAUM: 22.25B

News

latest 14 of 200

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-040.1400.0920.140180.29165.6710
2026Q22026-08-050.3000.1540.296218.25183.2810
2026Q12026-05-06-2.9800.044-2.980156.41151.129
2025Q42026-02-261.1200.0481.121406.56151.328
2025Q32025-11-030.0600.0400.059159.4162.9710
2025Q22025-08-040.0200.0070.023163.35149.8210
2025Q12025-05-050.000-0.0780.000145.53127.7911
2024Q42025-02-24-0.130-0.046-0.129131.53130.1510
2024Q32024-11-04-0.070-0.068-0.068117.09113.9910
2024Q22024-08-05-0.060-0.173-0.061109.3398.3011
2024Q12024-05-06-0.170-0.209-0.17292.7685.6211
2023Q42024-02-26-0.310-0.246-0.30793.4089.9711
2023Q32023-11-02-0.190-0.245-0.19186.7486.0610
2023Q22023-08-03-0.400-0.234-0.39882.4981.4210
2023Q12023-05-03-0.280-0.299-0.28368.7871.6911
2022Q42023-02-21-0.380-0.166-0.38379.5575.2311

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-0.940-1.219-0.94248.8418.97
2020FY-1.090-0.998-1.09317.8128.56
2021FY-1.030-1.219-1.028157.17160.4
2022FY-1.330-1.113-1.329270.83265.41
2023FY-1.180-1.055-1.179331.41327.97
2024FY-0.430-0.359-0.430450.71449.34
2025FY1.2100.1411.210874.84619.55
2026FY--2.290--718.43
2027FY-0.563--739.9
2028FY-0.643--830
2029FY-0.934--974.26
2030FY-1.411--1,161

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-041017165.8159.12172.88
2026Q4S2026-10-191010169.75163.38173.66
2026Q4S2026-09-291033169.75163.38173.66
2026Q4S2026-09-281033169.77163.38173.66
2026Q4S2026-09-071023169.22163.38173.66
2026Q4S2026-08-051023169.22163.38173.66
2026Q4S2026-07-291010170.52164.88183.31
2026Q4S2026-07-201010170.52164.88183.31
2026Q4S2026-07-171032170.52164.88183.31
2026Q4S2026-07-101023170.07162.4183.31
2026Q4S2026-07-06923170.35162.4183.31
2026Q4S2026-06-25923170.35162.4183.31
2026Q4S2026-05-12923170.35162.4183.3
2026Q4S2026-05-06934170.35162.4183.3

Estimate history

EPS, annual-0.78-0.981-0.942-1.093-1.028-1.329-1.179-0.431.207-1.421
Period201720182019202020212022202320242025TTM
EPS, quarterly-0.068-0.12900.0230.0591.121-2.980.2960.142
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual25.18620.65348.83517.812157.17270.827331.412450.712874.837961.51
Period201720182019202020212022202320242025TTM
Sales, quarterly117.085131.534145.534163.353159.395406.555156.413218.25180.292
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual98.411110.063154.082176.883184.35187.906205.771208.543213.06256.118
Period201720182019202020212022202320242025MRQ
Shares, quarterly207.119208.543209.208209.905210.522213.06254.014255.265256.118
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue961.51874.84450.71331.41270.83157.1717.8148.8420.65
Cost of Goods Sold Incl. D&A22.5220.4613.736.328.038.041.684.100.86
Gross Profit938.99854.37436.98325.10262.80149.1316.1444.7319.80
Selling, General and Administrative Excl. Other530.64513.38439.52428.81411.23326.85185.87144.19103.02
Research and Development209.16164.74173.39214.91251.86208.03122.96107.0784.89
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income408.34340.99-2.54-103.71-148.44-177.72-169.73-99.45-83.22
Interest Expense76.8178.8798.52108.2499.0959.2914.5011.8910.12
Unusual Expense709.6417.330.0029.021.98-55.14-0.230.3511.11
Net Income Before Taxes-354.73267.39-86.95-226.23-244.38-181.81-182.81-108.90-101.25
Income Taxes4.923.531.930.312.732.250.000.000.00
Consolidated Net Income-359.66263.86-88.88-226.54-247.12-184.06-182.81-108.90-101.25
Net Income From Continuing Operations-359.66263.86-88.88-226.54-247.12-184.06-182.81-108.90-101.25
Net Income-359.66263.86-88.88-226.54-247.12-184.06-182.81-108.90-101.25
EPS (Recurring)0.511.26-0.43-1.07-1.32-1.24-1.09-0.94-0.91
EPS (Basic, Before Extraordinaries)-1.361.26-0.43-1.18-1.33-1.03-1.09-0.94-0.98
EPS (Diluted)-1.421.21-0.43-1.18-1.33-1.03-1.09-0.94-0.98
EBITDA410.56342.38-1.30-102.05-147.00-176.94-168.98-98.73-82.45
Non-Operating Income (Expense)23.3822.6114.1114.745.130.061.192.803.19
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense54.3267.2051.6843.9435.3134.6414.7917.729.40
Price To Sales Ratio2.321.953.453.477.8815.7869.968.1740.32
Gross Margin97.6697.6696.9598.0997.0394.8890.5991.6095.86
Operating Margin42.4738.98-0.56-31.29-54.81-113.08-952.90-203.66-402.94
Net Margin-37.4130.16-19.72-68.36-91.24-117.11-1,026.35-222.99-490.25
Shares Outstanding256.12213.06208.54205.77187.91184.35176.88154.08110.06
Market Capitalization1,968.341,937.461,557.641,226.812,140.152,477.351,315.42531.50884.80

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue180.29218.25156.41406.56159.40163.35145.53131.53
Cost of Goods Sold Incl. D&A1.824.356.449.922.523.134.906.44
Gross Profit178.47213.90149.97396.64156.87160.23140.63125.09
Selling, General and Administrative Excl. Other125.14115.43153.81136.25127.28130.44119.41129.60
Research and Development57.9751.4659.2640.4744.2743.0636.9449.13
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income53.3398.47-3.84260.3829.5929.7921.23-4.51
Interest Expense21.1821.7119.7814.1319.6621.5823.4924.45
Unusual Expense0.000.00699.2210.422.744.170.000.00
Net Income Before Taxes38.5979.47-720.81248.0212.136.490.76-25.99
Income Taxes0.671.081.002.17-0.771.400.730.80
Consolidated Net Income37.9278.39-721.81245.8412.905.080.03-26.80
Net Income From Continuing Operations37.9278.39-721.81245.8412.905.080.03-26.80
Net Income37.9278.39-721.81245.8412.905.080.03-26.80
EPS (Recurring)0.140.30-0.961.150.070.040.00-0.13
EPS (Basic, Before Extraordinaries)0.150.31-2.981.170.060.020.00-0.13
EPS (Diluted)0.140.30-2.981.120.060.020.00-0.13
EBITDA53.5798.98-2.78260.7829.9330.1121.56-4.20
Non-Operating Income (Expense)6.442.722.0312.194.942.453.022.97
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense11.2511.6112.6618.8014.6916.8316.8816.86
Price To Earnings Ratio--7.91-----
Price To Sales Ratio2.322.822.601.952.783.533.213.46
Gross Margin98.9998.0195.8897.5698.4298.0996.6395.10
Operating Margin29.5845.12-2.4564.0518.5618.2314.59-3.43
Net Margin21.0335.92-461.4860.478.093.110.02-20.37
Shares Outstanding256.12255.26254.01213.06210.52209.91209.21208.54
Market Capitalization1,968.342,541.632,387.631,643.761,593.291,874.881,567.201,557.64

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments274.95321.06390.79425.78510.95302.59137.78106.01117.68
Short Term Receivables106.8279.0756.9550.6029.418.6522.154.296.12
Inventories5.408.0928.6827.5315.797.040.001.650.00
Other Current Assets17.1813.7519.5412.599.995.534.422.391.38
Total Current Assets404.35421.97495.97516.50566.14323.80164.34114.34125.18
Net Property, Plant & Equipment18.9919.7920.9915.4215.1910.9110.949.139.55
Total Investments and Advances62.5621.720.0018.086.830.000.0022.3841.30
Intangible Assets--0.000.000.000.000.00-0.00
Other Assets28.2626.940.000.000.000.000.000.992.24
Total Assets514.16490.42516.96550.00588.15334.71175.28146.84178.26
Short Term Debt Incl. Current Port. of LT Debt40.0835.4526.212.371.8231.1839.9633.7535.22
Accounts Payable15.8311.6420.8914.3627.8118.7113.997.776.34
Other Current Liabilities140.16113.29102.8888.7974.0955.7638.3927.9633.28
Total Current Liabilities196.07160.38149.99105.51103.72105.6592.3369.4874.84
Long Term Debt437.25805.97822.50739.08591.42123.6144.7028.0719.50
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities0.000.000.000.000.00124.720.000.050.15
Total Liabilities633.31966.35972.49844.60695.14353.98137.0397.6194.49
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.000.00
Common Equity-119.15-475.93-455.53-294.60-106.99-19.2638.2549.2383.77
Total Shareholders Equity-119.15-475.93-455.53-294.60-106.99-19.2638.2549.2383.77
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity-119.15-475.93-455.53-294.60-106.99-19.2638.2549.2383.77
Total Liabilities & Stockholders Equity514.16490.42516.96550.00588.15334.71175.28146.84178.26
Book Value Per Share-0.56-2.28-2.21-1.57-0.58-0.110.250.450.85
Tangible Book Value Per Share-0.56-2.28-2.21-1.57-0.58-0.110.250.450.85
Full-Time Employees43558053653135824614010085
Price to Book Ratio-4.85-3.32-2.77-8.82-23.87-68.4113.9018.044.80
Return on Assets52.53-17.65-42.46-43.42-39.89-71.69-67.61-62.29-49.07
Return on Equity------1,925.37-248.94-152.26-154.16
Return on Invested Capital82.95-26.93-61.73-55.60-38.00-175.20-131.29-130.97-63.70
Quick Ratio2.032.583.124.635.313.001.781.621.67
Current Ratio2.062.633.314.905.463.061.781.651.67

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-359.66263.86-88.88-226.54-247.12-184.06-182.81-108.90-101.25
Depreciation2.211.391.251.661.440.780.750.720.77
Other Funds (Non Cash)814.96121.53122.90162.14142.7733.0017.9819.4611.45
Funds from Operations457.52386.7835.26-62.74-102.91-150.28-164.09-88.71-89.03
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-106.95-56.90-87.28-32.40-58.958.1226.88-0.87-3.53
Cash from Operating Activities350.57329.88-52.02-95.14-161.85-142.16-137.22-89.58-92.56
Capital Expenditures-1.65-2.47-1.12-2.17-1.35-2.38-0.51-0.34-0.37
Net Assets From Acquisitions-489.480.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses-6.12-6.180.000.000.000.000.000.000.00
Purchase or Sale of Investments-43.92-5.5953.72-129.33-126.8918.19-6.3478.285.13
Purchase of Investments-401.35-262.24-266.76-514.41-244.28-10.01-49.82-3.02-62.61
Sale Or Maturity of Investments357.43256.65320.48385.08117.4028.2043.4881.3067.75
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.550.000.000.000.000.000.000.00
Cash from Investing Activities-541.16-13.6952.59-131.50-128.2415.80-6.8677.934.77
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock30.739.173.488.6814.9665.79110.5479.6256.25
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock30.739.173.488.6814.9665.79110.5479.6256.25
Proceedsfrom Stock Options0.000.000.000.000.0050.0093.2858.5053.40
Issuance or Reduction of Debt, Net169.82-332.770.0027.1473.070.0067.4519.486.25
Change in Long Term Debt169.82-332.770.0027.1473.070.0067.4519.486.25
Issuance of Long Term Debt395.050.000.00288.8573.070.00119.8719.4810.35
Reduction of Long Term Debt-225.23-332.770.00-261.710.000.00-52.420.00-4.10
Net Financing Active Other Cash Flow-12.26-8.85-9.24-3.340.00293.87124.710.000.00
Other Financing Activities Uses-12.26-8.85-9.24-3.340.000.000.000.000.00
Cash from Financing Activities188.29-332.44-5.7632.4888.03359.67302.7099.1062.50
Exchange Rate Effect-0.171.27-0.940.360.570.07---
Net Change in Cash-2.48-14.99-6.12-193.79-201.50233.39158.6287.45-25.29
Free Cash Flow348.92327.41-53.14-97.31-163.20-144.54-137.73-89.93-92.93
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.000.00
Price to Free Cash Flow6.395.21-------
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments375.52353.05239.25274.95213.45260.53
Short Term Receivables121.79110.76109.27106.8291.3391.18
Inventories13.746.065.995.405.235.04
Other Current Assets20.1114.8219.1117.1845.6741.71
Total Current Assets531.15484.68373.62404.35355.68398.46
Net Property, Plant & Equipment7.4821.6722.9818.9919.2420.00
Total Investments and Advances0.930.9321.5062.5641.0711.50
Other Assets51.5050.5746.9428.2630.4327.22
Total Assets591.07557.85465.05514.16446.42457.19
Short Term Debt Incl. Current Port. of LT Debt47.1946.8143.4140.0839.4737.75
Accounts Payable14.5811.4610.9615.835.578.59
Other Current Liabilities134.06150.57141.02140.16145.20130.82
Total Current Liabilities195.83208.85195.39196.07190.24177.16
Long Term Debt781.01789.83814.67437.25643.64701.17
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities11.6113.468.830.000.440.45
Total Liabilities988.451,012.141,018.89633.31834.31878.78
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity-397.38-454.29-553.84-119.15-387.89-421.59
Total Shareholders Equity-397.38-454.29-553.84-119.15-387.89-421.59
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity-397.38-454.29-553.84-119.15-387.89-421.59
Total Liabilities & Stockholders Equity591.07557.85465.05514.16446.42457.19
Book Value Per Share-1.55-1.78-2.18-0.56-1.84-2.01
Tangible Book Value Per Share-1.55-1.78-2.18-0.56-1.84-2.01
Full-Time Employees---435--
Price to Book Ratio-4.93-4.59-17.02-4.23-3.78-4.15
Return on Assets-69.33-75.79-96.9252.53-1.87-7.68
Return on Invested Capital9.8823.36-276.7477.295.041.82
Quick Ratio2.642.291.882.031.842.22
Current Ratio2.712.321.912.061.872.25

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income37.9278.39-721.81245.8412.905.08
Depreciation0.240.511.060.390.340.33
Other Funds (Non Cash)31.1928.19730.0225.5729.2532.98
Funds from Operations69.35107.099.27271.8142.4838.39
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital-36.66-3.11-71.404.23-1.372.38
Cash from Operating Activities32.69103.98-62.14276.0441.1140.77
Capital Expenditures-0.23-0.21-0.40-0.80-1.34-0.18
Net Assets From Acquisitions0.000.00-489.480.000.000.00
Sale of Fixed Assets and Businesses0.070.000.00-6.180.000.00
Purchase or Sale of Investments-78.71-109.94221.24-76.5014.3729.31
Purchase of Investments-140.21-135.630.00-125.50-58.63-29.34
Sale Or Maturity of Investments61.5025.70221.2449.0073.0058.65
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.550.00
Cash from Investing Activities-78.88-110.15-268.65-83.4913.5729.13
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock4.296.2519.510.682.673.43
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock4.296.2519.510.682.673.43
Proceedsfrom Stock Options0.000.000.000.000.000.00
Issuance or Reduction of Debt, Net-14.69-13.35394.57-196.71-60.34-75.71
Change in Long Term Debt-14.69-13.35394.57-196.71-60.34-75.71
Issuance of Long Term Debt0.000.00395.050.000.000.00
Reduction of Long Term Debt-14.69-13.35-0.48-196.71-60.34-75.71
Net Financing Active Other Cash Flow-1.38-3.69-1.19-6.00-0.63-0.87
Other Financing Activities Uses-1.38-3.69-1.19-6.00-0.63-0.87
Cash from Financing Activities-11.78-10.79412.90-202.04-58.30-73.15
Exchange Rate Effect0.01-0.04-0.07-0.07-0.471.36
Net Change in Cash-57.96-16.9982.04-9.56-4.09-1.90
Free Cash Flow32.45103.77-62.54275.2339.7740.59
Price to Free Cash Flow6.397.447.875.2235.03127.10

Revenue breakdown

License2025: 243.98M
ORLADEYO2024: 437.66M 2025: 601.84M
Other Income From Contract With Customer2024: 13.05M 2025: 29.02M
United States2024: 450.71M 2025: 874.84M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-3012.50%27.6M221.2M4.57M
2026-10-1512.11%26.6M219.7M4.09M
2026-09-3012.52%27.5M219.7M4.19M
2026-09-1515.87%34.9M219.7M4.51M
2026-08-3115.50%34.1M219.7M4.30M
2026-08-1415.01%32.9M219.5M4.59M
2026-07-3115.18%32.8M216.1M4.90M
2026-07-1514.52%31.2M214.9M5.07M
2026-06-3022.65%48.7M214.9M5.00M
2026-06-1519.02%40.6M213.6M5.12M
2026-05-2917.04%36.7M215.1M5.36M
2026-05-1516.76%36.1M215.5M5.50M
2026-04-3016.31%37.4M229.5M5.18M
2026-04-1517.02%38.5M226.4M5.42M
2026-03-3115.28%35.2M230.3M5.48M
2026-03-1316.28%37.5M230.3M4.49M
2026-02-2717.55%40.4M230.3M4.32M
2026-02-1317.71%40.3M227.7M4.15M
2026-01-3017.33%39.5M227.7M4.41M
2026-01-1522.33%43.2M193.4M4.58M

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call1.005.807.506.6024.14699.000.000.990-0.0140.000
call2.004.906.500.0012.4650.000.000.974-0.0240.001
call3.003.905.500.008.8140.000.000.961-0.0240.001
call4.002.804.500.006.6030.000.000.946-0.0230.001
call5.001.803.500.004.9910.000.000.925-0.0210.002
call6.000.253.001.935.03310.000.000.889-0.0190.002
call7.000.002.100.753.9181.000.000.705-0.0310.004
call8.000.050.200.110.5971,72715.000.404-0.0240.005
call9.000.000.150.051.0011,5561.000.169-0.0170.003
call10.000.000.250.051.3963,3780.000.131-0.0200.003
call11.000.000.400.041.69461.000.000.111-0.0200.002
call12.000.000.750.032.0081.000.000.100-0.0240.002
call13.000.000.750.002.2580.000.000.092-0.0250.002
call14.000.000.450.482.69913.000.000.113-0.0350.002
call15.000.000.750.002.6850.000.000.081-0.0270.002
call16.000.000.750.002.8710.000.000.077-0.0280.002
put1.000.000.050.007.1870.000.00-0.011-0.0130.000
put2.000.000.750.005.8150.000.00-0.026-0.0240.001
put3.000.000.750.004.1750.000.00-0.039-0.0230.001
put4.000.000.750.003.0410.000.00-0.054-0.0220.001
put5.000.000.100.001.9990.000.00-0.078-0.0180.002
put6.000.000.100.051.2862000.00-0.117-0.0160.002
put7.000.000.250.051.1311152.00-0.295-0.0310.004
put8.000.001.000.511.6893740.00-0.596-0.0230.005
put9.000.102.851.604.17079.000.00-0.831-0.0160.003
put10.001.653.102.583.1111.000.00-0.869-0.0190.003
put11.002.554.100.003.5450.000.00-0.888-0.0210.002
put12.003.505.100.003.9160.000.00-0.900-0.0220.002
put13.004.506.100.004.2410.000.00-0.908-0.0240.002
put14.005.507.200.004.7650.000.00-0.915-0.0250.002
put15.006.508.200.005.0280.000.00-0.919-0.0250.002
put16.007.509.200.005.2670.000.00-0.923-0.0260.002

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10SCHEDULE 13GSEC
2026-11-0410-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-048-KCurrent report2026-11-04SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-09-024Statement of changes in beneficial ownership of securities2026-08-31SEC
2026-08-14SCHEDULE 13G/ASEC
2026-08-07SCHEDULE 13GSEC
2026-08-0510-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-05S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-058-KCurrent report2026-08-05SEC
2026-08-048-K/A2026-06-25SEC
2026-06-298-KCurrent report2026-06-25SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-154Statement of changes in beneficial ownership of securities2026-06-11SEC
2026-06-128-KCurrent report2026-06-11SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC
2026-06-024Statement of changes in beneficial ownership of securities2026-05-29SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-090000
2026-080000
2026-070000
2026-060000
2026-0500696.53K2
2026-040000
2026-03001.88M2
2026-020000
2026-010000
2025-12001.49M5
2025-110068.54K1

Institutional holders

Manager% owned
BlackRock, Inc.9.40%
RA CAPITAL MANAGEMENT, L.P.6.23%
STATE STREET CORP5.98%
DEERFIELD MANAGEMENT COMPANY, L.P.5.94%
VANGUARD CAPITAL MANAGEMENT LLC4.47%
VANGUARD PORTFOLIO MANAGEMENT LLC4.38%
TCG Crossover Management, LLC4.34%
PERCEPTIVE ADVISORS LLC4.06%
Jupiter Topco LLC3.75%
Vestal Point Capital, LP3.27%

Funds

Fund% owned
State Street(R) SPDR(R) S&P(R) Biotech ETF3.77%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.17%
High Yield Fixed Income Fund3.15%
iShares Russell 2000 ETF2.38%
VANGUARD SMALL-CAP INDEX FUND1.15%
VANGUARD EXTENDED MARKET INDEX FUND1.12%
Fidelity Small Cap Index Fund1.00%
abrdn Healthcare Investors0.91%
VANGUARD STRATEGIC EQUITY FUND0.89%
iShares Russell 2000 Growth ETF0.85%

OakChart. BCRX. Cached 15 minutes.